Bruker Daltonics Introduces New Proteineer Tools for Expression Proteomics: Proteineer-LC system and Top-Down Proteineer.

Business Editors/Health/Medical Writers/High-Tech Writers

52nd ASMS Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--May 24, 2004

At the 52nd ASMS conference, Bruker Daltonics, an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), today announces its new Proteineer-LC, a new LC-ESI-MALDI system for LC-based expression proteomics workflows. Moreover, Bruker Daltonics also introduced the new Top-Down Proteineer (TopPro(TM)) capability on its apex-Qe(TM) Q-q-FTMS system, allowing identification, primary structure determination and localization of post-translation modifications (PTMs) directly at the protein level, without the need for enzymatic digests.

Proteineer-LC

Proteineer-LC combines multi-LC-MS/MS proteomics approaches, e.g. using ESI ion trap mass spectrometry, with a new optimized sample splitting and MALDI fraction collection device, called Proteineer-FC. This enables a seamless LC-MALDI-MS/MS proteomics workflow with our TOF/TOF systems at high sensitivity, using our patented Anchorchip sample plate technology.

Information-dependant workflows can be utilized so that tentative protein IDs can be confirmed in an intelligent, results-driven way by our WARP-LC(TM) software. WARP-LC can analyze LC-MS(n) results from our HCTplus high capacity ion trap on the fly and then direct targeted MALDI-TOF/TOF experiments, based on the initial database search results. The combined information significantly increases ID success rates, allows identification of lower abundance proteins and enables further PTM characterization without LC time constraints using the LC-MALDI-TOF/TOF workflow.

Top-Down Proteineer

The unique Top-Down Proteineer (TopPro(TM)) is now available on the apex-Qe(TM) hybrid Q-q-FTMS system launched earlier this year. It combines the analytical power of FTMS equipped with a hybrid ESI-Q-q interface to perform "top-down" analysis of intact proteins in the FTMS analyzer cell, thus avoiding digestion and additional separation steps. The enormous resolving power of the FTMS is ideal for measuring protein fragment ions generated directly with electron-capture dissociation (ECD) in the FTMS analyzer cell, and can deliver high fidelity long sequence runs, as well as information on the localization of PTMs. Our unique ability for efficient selective ion enrichment using selected ion injection via the analytical quadrupole of the Q-q-FTMS extends the overall systems dynamic range and sensitivity by one to two orders of magnitude. MS Biotools software handles the database searching interface and confirms sequence annotations on the fly.

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.

(Note to Editors: There is a down-arrow in the symbol of "Top-Down Proteineer" in between "Top" and "Pro".)